Ischemic And Bleeding Risk Assessment After TAVR
Recruiting
Observational Study
Aortic Valve Stenosis
Transcatheter Aortic Valve Replacement
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,500 (estimated)
- Sponsor
- Niguarda Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2).
Giving an established uniform approach towards anticoagulation and antithrombotic therapy after TAVR in the post POPULAR-TAVI era, recent data coming from the analysis of different trials, highlight the relevance of the p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* All patients with severe aortic stenosis undergoing TAVR.
* Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.
Exclusion Criteria
* Patients who died during the index procedure
* Patients in triple antithrombotic therapy at discharge…
Contacts